Stockreport

Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential [Seeking Alpha]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF The company's relutrigine achieved a 46% placebo-adjusted reduction in motor seizure frequency for SCN2A/SCN8A DEE and is under FDA priority review with a PDUFA date of [Read more]